Quarterly revenue growth up 135% year-on-year, with total revenues passing ₹2000 crore for the first time
Neuland Laboratories, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has reported its best ever quarterly revenue figures [circa $83m*].
The CDMO, which invested heavily in commercial-scale API and peptide manufacturing capacities, said commercial projects from North American customers were the primary driver of revenue growth during the quarter. In fact, Q4 FY26 [January – March end 2026] revenues were up nearly 135% on the same period last year.
In another major milestone for the CDMO, total revenues for the full financial year [2026] passed ₹2000 Crore [INR] for the first time, equivalent to approximately $215m [USD]. Additionally, EBITDA for Q4 FY26 was up nearly 449% year-on-year to $33M [₹319.4 crore], representing an EBITDA margin of 40%. Profit after tax for the quarter reached ₹212.5 crore (approximately $22 million).
Commenting on the performance Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories, added: “We are delighted to have ended FY26 on an incredibly strong note and there is also a strong business visibility both in the short and medium, anchored by a robust customer pipeline of commercial and near-commercial molecules.“
Earlier this year, the CDMO announced a major phased investment in a new commercial peptide facility, with peptide therapeutics expected to represent a significant future growth opportunity. Davuluri added “We are not resting on this recent momentum and are already laying the groundwork for growth beyond this horizon, with both a new R&D Centre and peptide manufacturing site progressing well. Our business development strategy is aligned to supporting these investments and driving continued sustainable growth. At the core of our success is a company-wide focus on execution discipline, customer satisfaction, and maintaining an exemplary regulatory track record.”
Neuland operates 12,18,000 litres of API manufacturing capacity across three US FDA–approved facilities, supported by a large dedicated R&D Centre located in close proximity to its manufacturing sites. This integrated setup enables seamless scale-up, rapid technology transfer and highly efficient development-to-commercial execution.
